Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific Names Recipients of RNAi Discovery Grants

Published: Friday, November 06, 2009
Last Updated: Friday, November 06, 2009
Bookmark and Share
More than $400,000 in RNAi screening tools awarded to advance biomedical research and drug discovery.

Thermo Fisher Scientific Inc has announced the recipients of more than $400,000 in RNA-interference (RNAi) reagents to advance biomedical research and drug discovery.

The awards were made through the Thermo Scientific RNAi Discovery Grant Program. Five projects were chosen based on the potential of the research to advance science and medicine. The recipients will receive various siRNA, shRNA and microRNA reagents from the Dharmacon and Open Biosystems RNAi technology portfolios, marketed under the Thermo Scientific brand.

D. Borden Lacy, assistant professor, and Terence S. Dermody, professor of pediatrics, microbiology and immunology at Vanderbilt University, will receive a whole genome small-interfering RNA (siRNA) screening package to investigate pathogen cell entry. These researchers hope to identify host proteins that form networks required for diverse microbial pathogens (viruses and bacterial exotoxins) to enter living cells. They expect these networks to open new avenues for research into host-pathogen interaction and point to new drug targets.

“We are honored to receive an RNAi Discovery Grant from Thermo Fisher Scientific,” said Dermody. “It will allow us to combine our efforts in studies of how bacterial toxins and viruses gain entry into host cells and may lead to development of new classes of antimicrobial agents.” Lacy added, “We would not have been able to do this work without the RNAi Discovery Grant, and we are excited to get started.”

Roger Lippe, associate professor, in the Department of Pathology and Cell Biology at the University of Montreal, will receive a custom siRNA sub-library targeting human genes. The sub-library will be used to identify cellular proteins interacting with HSV-1 (herpes simplex virus type 1). The goal is to identify host proteins implicated in propagation of HSV-1 and understand their relevance and function for the virus.

Caitlin Conboy, graduate student and David Largaespada, professor of the Masonic Cancer Center and Center for Genome Engineering, University of Minnesota, will receive a custom short-hairpin RNA (shRNA) sub-library targeting human genes. Using results from a transposon-based genetic screen, they will use shRNA to functionally validate genes required for generation and growth of tumors in colorectal cancer.

A set of human colorectal cancer and normal colonic epithelium cell lines will be treated with shRNA and then analyzed for alterations in the Wnt/beta-catenin pathway, including signaling, proliferation, cell cycle, apoptosis, invasion and anchorage-independent growth. The team expects to identify both positive and negative regulators of tumor production, which ultimately may point to candidates for drug targeting.

Christopher J. Lord, senior staff scientist, and Alan Ashworth, professor and director of the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London, will receive a microRNA (miRNA) library to optimize new cancer drugs that show promise in treating certain types of breast and ovarian cancer.

In clinical tests, these drugs, known as PARP inhibitors, have been successful in shrinking tumors in many patients without the side effects associated with standard chemotherapies. The researchers hope to identify miRNAs that affect a patient’s response to PARP inhibitors and then develop clinical biomarkers to predict which patients are more likely to respond favorably or be resistant to the drugs.

"It's been clear to us for some time now that genetic screens are incredibly useful in helping us understand many of the complex issues in cancer biology and treatment,” said Lord. “The RNAi screening reagents that Thermo Fisher has developed are key to this genetic approach, and we know that these days one can translate the findings from an RNAi screen very rapidly into something that is clinically relevant.”

Xiaofeng Zhou, assistant professor at the University of Illinois in Chicago, will receive a miRNA library to identify microRNAs that contribute to enhanced cancer cell invasion and migration. An essential characteristic of cancer is the ability to invade surrounding tissues and metastasize to regional and distant sites. Several recent studies suggest links between metastasis, which is the most deadly aspect of cancer, and unique microRNA changes. Zhou will specifically study head and neck cancer cell lines with different metastatic potential, and his goal is determine if microRNA deregulation affects this potential.

“We are delighted that our RNAi Discovery Grant program will advance research into key areas of medical science,” said Mitchell Kennedy, vice president and general manager, Thermo Scientific Genomics. “These RNAi screening technologies will help accelerate important biological discoveries that may lead to better treatments for some of the most devastating diseases facing humanity.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Fisher Q3 Revenues up 31 Percent
Thermo Fisher announced that revenues grew 31% to $4.17 billion for the third quarter ended September 27, 2014.
Thursday, October 23, 2014
Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
Companies pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs.
Monday, June 02, 2014
Thermo Reports 22% Revenue Rise in Q1 2014
Results include the addition of Life Technologies as of February 4, 2014, and exclude the previously announced related divestitures as of March 22, 2014.
Wednesday, April 23, 2014
Thermo Reports 6% Q4 Revenue Growth
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2013.
Friday, January 31, 2014
Thermo Scientific Forms Technology Alliance Partnership With University of Birmingham
Collaboration aimed at advancing LC-MS techniques in life science research.
Friday, March 29, 2013
Record Revenues for Thermo Fisher Scientific
Revenue for the quarter grew 6% to $3.26 billion in 2012, versus $3.09 billion in 2011.
Thursday, January 31, 2013
Thermo Fisher Scientific and NUS Form Collaboration
Goal to develop mass spectrometry-based techniques to study metabolites.
Monday, January 28, 2013
Thermo Fisher Scientific and Intrinsic Bioprobes Collaborate to Develop MS Immunoassay Workflow
Turnkey MSIA solution allows researchers to differentiate and quantitate low-abundance intact proteins and their variants.
Friday, July 16, 2010
Thermo Fisher Scientific Launches Maybridge Ro3 Diversity Fragment Library
Diverse set of 1,500 molecules engineered for high-quality fragment screening-based programmes.
Tuesday, July 06, 2010
Thermo Fisher Scientific Collaborates with Leading Proteomics Researcher in Luxembourg
Collaboration aims to develop workflows to overcome current bottlenecks in biomarker discovery and assay development for clinical proteomics research.
Monday, April 26, 2010
Thermo Fisher Scientific, GMU, Johns Hopkins and Toronto’s UHN Extend Collaboration
Accelerating biomarker identification for cancer and other diseases may speed development of diagnostic tests that enable earlier disease detection.
Wednesday, March 31, 2010
Thermo Fisher Scientific Collaborates with Expression Pathology
The collaboration will apply both companies’ expertise for identification of cancer-related proteins.
Friday, December 18, 2009
Thermo Fisher Scientific and Symyx Technologies to Deliver Integrated LIMS and ELN Solutions to Scientists
Thermo Fisher Scientific Inc., today announced the release of a joint product development effort resulting from its partnership with Symyx Technologies.
Tuesday, October 27, 2009
Thermo Fisher Scientific Introduces Linear Ion Trap Trade-Up Program for Single Quadrupole and Ion Trap LC-MS Users
Thermo Fisher Scientific Inc. today announced the introduction of a new program that invites scientists to trade in their single quadrupole or ion trap mass spectrometer - from any vendor - and upgrade to leading Thermo Scientific linear ion trap technology
Wednesday, October 07, 2009
Thermo Fisher Scientific Signs Agreement to Acquire B.R.A.H.M.S. AG
Company acquires provider of specialty in-vitro diagnostic tests for $470 million USD.
Monday, September 07, 2009
Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Can Cell Cycle Protein Prevent or Kill Breast Cancer Tumors?
An MD Anderson study has shown the potential of a simple molecule involved in cancer metabolism as a powerful therapeutic.
Study Reveals Improved Way to Interpret High-Throughput Biological Data
A recent study has revealed a novel workflow, identifying associations between molecules to provide insights into cellular metabolism and gene expression in complex biological systems.
Optical 'Dog's Nose' Developed to Detect Cancer, Other Diseases
Researchers are using optical spectroscopy to develop a quick, non-invasive “breath test” they believe will have the potential to screen for a variety of diseases, including diabetes, infections and cancers.
Researchers Link Liver Disease and Drug Metabolism
Researchers have discovered that nonalcoholic steatohepatitis, an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes.
Scientists Create Synthetic Membranes That Grow Like Living Cells
Chemists and biologists at UC San Diego have succeeded in designing and synthesizing an artificial cell membrane capable of sustaining continual growth, just like a living cell.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Team Led by TSRI Scientists Shows AIDS Vaccine Candidate Successfully ‘Primes’ Immune System
New research shows that an experimental vaccine candidate can stimulate immune activity necessary to prevent HIV infection.
The Perfect Partnership: Research & Industry; Software & Instrumentation. It really starts to come together at ASMS 2015
Collaboration and knowledge-sharing were evident everywhere: on the bus, in the hallways and in the bars. This article aims to capture this theme and share with you some of the fruits of this coming together of science and industry.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!